RS BioTherapeutics, Inc.

We at RS BioTherapeutics, Inc. are incredibly thankful for the service and sacrifices of our country’s veterans and those who continue to serve to protect our country and the liberties we hold so dear. Hoping they and all have a safe and enjoyable Veterans Day.

At RS Bio, we are constantly striving to optimize the drug development process by implementing strategies offering high translational value. Studies using human lung slices, often referred to as Precision Cut Lung Slices (PCLS), do just that. PCLS are primarily used to investigate various aspects of lung function, disease mechanisms, and drug responses in a physiologically relevant ex vivo model, including areas like inflammation and fibrosis. They can also be used to study the effects of lung diseases like COPD and pulmonary fibrosis by analyzing cellular responses within the tissue slices to different stimuli. The figure below from a 2024 article by Cynthia Koziol-White from the Rutgers Institute for Translational Medicine and Science highlights the range of processes that can be measured utilizing PCLS. RS BioTherapeutics, Inc. will soon be testing our first-in-class, steroid-free compound for its ability to attenuate inflammation and fibrosis in an inducible, human PCLS model, which is clinically relevant for??COPD and Idiopathic Pulmonary Fibrosis (IPF) respectively. We are optimistic that the high translational value will provide valuable insights for our continued development of RSBT-001 and future clinical trials.? We look forward to sharing those study results in the coming months as we continue to work towards improving the lives of patients suffering from deadly lung diseases like COPD, IPF, and PAH.?

Did you know September is Pulmonary Fibrosis Awareness Month? This year the theme is “Every breath, every story” and the goal is to showcase how the pulmonary fibrosis community stands together in the fight against this disease. At RS BioTherapeutics, Inc. we are committed to fighting deadly lung diseases by providing an innovative, first-in-class solution for lung diseases characterized by pulmonary inflammation, including COPD, IPF, and more.? The Pulmonary Fibrosis Foundation has put together an incredible campaign to raise awareness and highlight the community. The "30 Facts In 30 Days" series is one of our favorites – below is the first one! Check their page for more. #PFMonth?#BlueUp4PF?#respiratory #research #innovation

From our CEO, Dean Hart...

We are proud to announce that we have submitted two proposals to the Toxic Exposures Research Program (TERP) in support of RSBT-001, a first-in-class therapeutic agent aimed at treating deadly lung diseases associated with pulmonary inflammation. The goals of TERP—preventing, minimizing, and mitigating the impact of military-related toxic exposures—strongly align with our dedication to improving the health and quality of life for those affected by deadly lung conditions. Military personnel are often exposed to a range of harmful substances, leading to complex and debilitating health issues, including chronic lung diseases such as COPD. Our submissions address the long-term impact of these types of exposures. By submitting to TERP, we aim to contribute to the advancement of scientific understanding and the development of effective healthcare solutions to support veterans and active service members who have sacrificed so much.

On this Thursday, July 25th, our CEO Dean Hart will host a webinar for our community. Register NOW using the link below to secure your spot! https://lnkd.in/ehXkXmwr This webinar is an excellent opportunity for you to ask questions, engage directly with our CEO, and learn more about how RS BioTherapeutics, Inc. is making a difference in the lives of patients with deadly lung diseases.?

On Thursday, July 25th,?our CEO Dean Hart will be hosting a webinar to share updates regarding the development of our lead compound RSBT-001, the large market opportunity, our latest collaborations, and why we think RSBT-001 can make a significant difference in the lives of the millions of patients suffering from deadly lung diseases like COPD, Idiopathic Pulmonary Fibrosis (IPF), and Pulmonary Arterial Hypertension (PAH). We hope to see you there! Registration link and details can be found on the Event page.

We are excited to announce our research collaboration with the University of Colorado School of Medicine. Click below to read the full press release!

?????Celebrating Our Country’s Independence!????? Here at RS BioTherapeutics, Inc. we feel fortunate to live in a country where we are afforded the liberty to pursue our mission of changing the world for the millions of patients suffering from deadly lung diseases. Those same liberties allow platforms like StartEngine to exist where individuals who would never have the opportunity to invest in early-stage pharmaceutical companies such as RS BioTherapeutics can do so. Of course, freedom isn’t free, and on July 4th?we will not only be celebrating our country’s independence but also remembering those who allowed us to enjoy this holiday and the liberties that are ingrained within it. From our families to yours, we wish you a safe and enjoyable Independence Day holiday and weekend! ????

The current guideline recommended therapies for IPF have limited efficacy and are strongly associated with tolerance issues. RS BioTherapeutics, Inc. is committed to providing an innovative, first-in-class solution to combatting deadly lung diseases characterized by pulmonary inflammation, including IPF. Our lead asset, RSBT-001, possesses a multi-targeted approach to addressing pulmonary inflammation. THE ROLE OF INFLAMMATION IN IPF Inflammation plays a complex and critical role in the development and progression of IPF. In the context of IPF, inflammation is part of the body’s response to lung injury. When the lungs are injured, the immune system responds by causing inflammation, which is the body’s attempt to heal the damaged tissue. However, in IPF, this inflammation does not resolve properly and instead leads to further damage and scarring (fibrosis) of the lung tissue. This scarring thickens the lung tissue and makes it stiff, hindering the ability to breathe and absorb oxygen effectively. The inflammatory process in IPF involves various immune cells and mediators. Key players include alveolar macrophages, which are immune cells in the lungs that release signaling molecules called cytokines. These cytokines recruit other immune cells to the site of injury, perpetuating the inflammatory response. Over time, this persistent inflammation contributes to the formation of excessive scar tissue, making the lung tissue stiff and impairing its ability to function normally. Interested in supporting our efforts? Please see the opportunities on our StartEngine page: https://lnkd.in/exTBcb6Z Source: Ishida Y, Kuninaka Y, Mukaida N, Kondo T. Immune Mechanisms of Pulmonary Fibrosis with Bleomycin.?International Journal of Molecular Sciences. 2023; 24(4):3149.?https://lnkd.in/eKcph4x4 #research #IPF